Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents-Reference-Cited by-同舟云学术

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Published:2017-02-13 Issue:4 Volume:92 Page:351-358
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Jabbour Elias¹^ORCID,Strati Paolo¹^ORCID,Cabrero Monica¹,O'Brien Susan¹,Ravandi Farhad¹,Bueso-Ramos Carlos²,Wei Qiao³,Hu Jianhua³,Abi Aad Simon¹,Short Nicholas J.¹^ORCID,Dinardo Courtney¹,Daver Naval¹,Kadia Tapan¹,Wierda William¹,Wei Yue¹,Colla Simona¹,Borthakur Gautam¹,Cortes Jorge¹,Estrov Zeev¹,Kantarjian Hagop¹,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia; University of Texas M.D. Anderson Cancer Center; Houston Texas 77030 USA

2. Department of Hematopathology; University of Texas M.D. Anderson Cancer Center; Houston Texas 77030 USA

3. Department of Biostatistics; University of Texas M.D. Anderson Cancer Center; Houston Texas 77030 USA

Funder

University of Texas MD Anderson Cancer Center

International Parkinson and Movement Disorder Society

Publisher

Wiley

Subject

Hematology

Reference26 articles.

1. Myelodysplastic syndromes;Tefferi;N Engl J Med.,2009

2. Cause of death in patients with lower-risk myelodysplastic syndrome;Dayyani;Cancer.,2010

3. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol.,2002

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol.,2009

5. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer.,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring molecular changes in the management of myelodysplastic syndromes;British Journal of Haematology;2024-06-27

2. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes;Blood Advances;2023-08-10

3. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms;The Cancer Journal;2023-05

4. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes;Blood;2023-02-01

5. Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience;Leukemia Research;2023-01